Ipsen S.A.
Status: Publicly traded
Direct answer
Ipsen S.A. is publicly traded on PAR under the ticker IPN.PA.
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the...
Can you invest in Ipsen S.A.?
Yes. Ipsen S.A. trades publicly on PAR as IPN.PA.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Detailed equity research is provided by MarketSnap.